Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications

Ruben Mesa, Jeanne Palmer, Ryan Eckert, Jennifer Huberty

Research output: Contribution to journalReview articlepeer-review

Abstract

Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.

Original languageEnglish (US)
Pages (from-to)375-390
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume35
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • Inflammation
  • Integrative medicine
  • Myeloproliferative neoplasm
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications'. Together they form a unique fingerprint.

Cite this